30 closest matches · ranked by relevance
Hematologic Malignancies · Bone Marrow Transplant Rejection
Primary: The Proportion of Patients Who Develop Full Donor T Cell Chimerism at Day 30 — 44.9 percentage of participants
Chronic Myelogenous Leukemia · Acute Myelogenous Leukemia · Chronic Lymphocytic Leukemia
Primary: Survival and Non-relapse Mortality at Day +200 Using the Miltenyi Reagent System — 43; 4 participants
MDS (Myelodysplastic Syndrome) · Myeloproliferative Disorder · Lymphoma, Non-Hodgkin
Primary: Overall Survival — 36 Participants
Multiple Myeloma
Primary: Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS) — 0.31 Proportion of participants PFS
Hematologic Neoplasms
Primary: Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for…
Diamond-Blackfan Anemia · Kostmann's Neutropenia · Shwachman-Diamond Syndrome
Primary: Number of Patients Alive (Survival) at 2 Years — 6 Participants
Dyskeratosis Congenita · Aplastic Anemia
Primary: Neutrophil Engraftment — 15; 20 Participants
Myeloproliferative Disorders · Acute Myelogenous Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Participants Who Experienced Transplant Related Mortality — 5; 4 Participants
Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA) · Severe Aplastic Anemia (SAA)
Primary: Number of Participants Who Engrafted by Day 42 — 30 Participants
Myelodysplastic Syndrome · Hodgkin's Lymphoma · Non-Hodgkin's Disease
Primary: Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD) — 42; 38 percentage of participants
Inherited Immune Deficiencies
Primary: Stem Cell Transplant Engraftment — 7; 31; 3; 0 Participants
CML (Chronic Myelogenous Leukemia) · CLL (Chronic Lymphocytic Leukemia) · AML (Acute Myelogenous Leukemia)
Primary: To Determine if Selective T Cell Depletion Using the Photodepletion Procedure Can Substantially Reduce the Rate of Severe Acute GVHD (Grade III/IV) After Matched Sibling…
Hematologic Malignancy
Primary: Number of Participants That Experience One Year Relapse Free Survival After Undergoing Hematopoietic Stem Cell Transplant (HSCT) — 5 Participants
Anemia, Aplastic · Amegakaryocytic Thrombocytopenia · Diamond-Blackfan Anemia
Primary: Treatment Failures
Dyskeratosis Congenita · Aplastic Anemia
Primary: Incidence of Neutrophil Engraftment — 100; 100; 96; 100 Percentage of participants
Graft-Versus-Host Disease
Primary: The Percentage of Participants Experiencing Acute GVHD After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — 45; 18 percentage of participants
Leukemia, Acute Lymphocytic (ALL) · Leukemia, Myeloid, Acute(AML) · Leukemia, Myeloid, Chronic(CML)
Primary: Event-free Survival (EFS) — 54.8 Percentage of participants
Blood Stem Cell Transplant Failure · Leukemia · Hematologic Malignancies
Primary: Number of Participants With Non-relapse Mortality (NRM) — 8; 7; 2; 0 Participants
Allogeneic Stem Cell Transplantation · Refractory Autoimmune Cytopenia(s)
Primary: Number of Participants With Response — 3; 2; 1 participants
Acute Lymphoblastic Leukemia · Non Hodgkins Lymphoma · Myelodysplastic Syndrome
Primary: Engraftment Rate After Transplant — 100; 100 percentage of participants
Leukemia · Lymphoma · Myelodysplastic Syndromes
Primary: Rates of Durable Engraftment — 17.9; 15.75; 13; 18.25 days
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Treatment-related Mortality Within the First 6 Months After Transplantation — 6 participants
Leukemia
Primary: Median Time to Engraftment of Neutrophils — 11; 11 days
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute · Burkitt Lymphoma
Primary: Overall Survival at 180 Days From the Time of Transplant — 73.5; 54.0 percentage of participants
Graft Versus Host Disease · Hematopoietic/Lymphoid Cancer
Primary: 12 Month Disease Free Survival Probability — 51.8 percentage of participants
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Day 100 TRM — 4 Participants
Hematopoietic/Lymphoid Cancer
Primary: Count of Participants That Experience 1 Year Relapse Free Survival After Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Using the Thomas Jefferson University…
Allogeneic Stem Cell Transplant · Leukemia · Non-Hodgkins
Primary: Overall Survival of Transplant Patients — 727.5 Days
Sickle Cell Disease · Thalassemia · Severe Congenital Neutropenia
Primary: Number of Patients Who Experienced Grade 3-5 Treatment Related Toxicity — 0; 0; 2 Participants
Systemic Scleroderma · Severe Systemic Sclerosis
Primary: Event-free Survival (EFS) — 1 Participants